Research Papers:

This article has been corrected. Correction in: Oncotarget. 2019; 10:2236.

Combined inhibition of PI3K and Src kinases demonstrates synergistic therapeutic efficacy in clear-cell renal carcinoma

Caroline Roelants, Sofia Giacosa, Catherine Pillet, Rémi Bussat, Pierre Champelovier, Olivier Bastien, Laurent Guyon, Valentin Arnoux, Claude Cochet and Odile Filhol _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2018; 9:30066-30078. https://doi.org/10.18632/oncotarget.25700

Metrics: PDF 1535 views  |   HTML 3141 views  |   ?  


Caroline Roelants1,2, Sofia Giacosa1, Catherine Pillet3, Rémi Bussat1, Pierre Champelovier4, Olivier Bastien5, Laurent Guyon1, Valentin Arnoux4, Claude Cochet1 and Odile Filhol1

1Université Grenoble-Alpes, Inserm U1036, CEA, BIG-BCI, Grenoble, France

2Inovarion, Paris, France

3Université Grenoble-Alpes, Inserm U1038, CEA, BIG-BGE, Grenoble, France

4Centre Hospitalier Université Grenoble-Alpes, CS 10217, Grenoble, France

5Université Grenoble-Alpes, CNRS-CEA-INRA, Laboratoire de Physiologie Cellulaire et Végétale, Grenoble, France

Correspondence to:

Filhol Odile, email: [email protected]

Keywords: kidney cancer; synthetic lethality; 3D culture; protein kinase; targeted combinational therapy

Received: January 26, 2018    Accepted: June 12, 2018    Published: July 10, 2018


Potent inhibitors of PI3K (GDC-0941) and Src (Saracatinib) exhibit as individual agents, excellent oral anticancer activity in preclinical models and have entered phase II clinical trials in various cancers. We found that PI3K and Src kinases are dysregulated in clear cell renal carcinomas (ccRCCs), an aggressive disease without effective targeted therapies. In this study we addressed this challenge by testing GDC-0941 and Saracatinib as either single agents or in combination in ccRCC cell lines, as well as in mouse and PDX models. Our findings demonstrate that combined inhibition of PI3K and Src impedes cell growth and invasion and induces cell death of renal carcinoma cells providing preclinical evidence for a pairwise combination of these anticancer drugs as a rational strategy to improve renal cancer treatment.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 25700